KCNJ10 and myeloid sarcoma: They reported that only 7.5% of 268 patients with MS had anti-Kir4.1 antibodies, and that this proportion did not significantly differ from those of HCs or patients with OND; an immunofluorescence analysis did not detect any specific staining patterns.